ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	391	226.45	-61.29	-215.98	-167.87
Depreciation & Amortization	11.76	15.88	5.55	-	3.34
Stock-Based Compensation	52.14	67.05	66.42	68.2	63.62
Other Adjustments	-255.3	-155.82	-12.12	-4.25	0.08
Change in Receivables	-43.54	-2.35	-39.27	2.26	-15.06
Changes in Inventories	-18.2	-49.55	-28.81	2.42	-4.21
Changes in Accounts Payable	-5.29	-1.35	4.8	5.87	-1.62
Changes in Accrued Expenses	-19.27	71.06	93.17	24.31	-8.46
Changes in Other Operating Activities	-3.47	-13.66	-11.76	3.14	4.52
Operating Cash Flow	109.84	157.72	16.7	-114.04	-125.66
Operating Cash Flow Growth	-30.36%	844.31%	-	-	-
Capital Expenditures	-4.69	-0.52	-0.05	-	-1.12
Sale of Property, Plant & Equipment	-	146.52	-	-	-
Purchases of Intangible Assets	-98.84	-	-40	-	-
Purchases of Investments	-692.57	-505.1	-369.99	-363.17	-492.8
Proceeds from Sale of Investments	493.53	328.57	442.03	436.42	422.82
Investing Cash Flow	-302.56	-30.54	32	73.24	-71.1
Issuance of Common Stock	49.88	6.85	25.13	8.2	18.16
Net Common Stock Issued (Repurchased)	49.88	6.85	25.13	8.2	18.16
Financing Cash Flow	49.88	6.85	25.13	8.2	18.16
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.03	-0.09	-0.02	0.01	0.01
Net Cash Flow	-142.82	133.93	73.81	-32.59	-178.59
Free Cash Flow	105.15	157.2	16.65	-114.04	-126.78
Free Cash Flow Growth	-33.11%	844.01%	-	-	-
FCF Margin	9.81%	16.41%	2.29%	-22.05%	-26.19%
Free Cash Flow Per Share	0.62	0.94	0.10	-0.71	-0.79
Levered Free Cash Flow	351.85	248.31	1.62	-180.25	-175.41
Unlevered Free Cash Flow	255.88	224.37	-25.21	-190.52	-178.34

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q